Last edition
News about "Shanghai Pharmaceutical Co., Ltd. (Shaphar) "
Boan Biotech's Dulaglutide Biosimilar 'Boyouping' Approved for Marketing in China
Boan Biotech announced that China’s National Medical Products Administration (NMPA) has granted marketing approval to its Boyouping (dulaglutide injection), indicated for glycemic control in adults with type 2 diabetes mellitus.
Shanghai Pharmaceutical Co., Ltd. (Shaphar) | 11/08/2025 | By Dineshwori | 578
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members